admin

About admin

This author has not yet filled in any details.
So far admin has created 13 blog entries.

Percentage of Pets Covered By Insurance Continues to Grow

One in four dogs will be diagnosed with cancer in their lifetimes, and that’s only one of many diseases that can present a pet owner with a difficult health decision for their pet. This article highlights that an increasing number of pet owners are choosing to mitigate the financial challenges inherent in advanced treatments by purchasing pet insurance. According to Sarah A. Moser in a recent DVM360 article, the percentage of pets covered by insurance continues to grow, and looks to be accelerating with the millennial generation owning an ever increasing percent of total dogs and cats. Our inquiries indicate that ECI® from ELIAS is covered by many insurance companies today, when prescribed by a veterinarian. veterinarybusiness.dvm360.com/future-trend-millennials-could-be-boost-pet-insurance-needs

By |2019-01-15T12:31:55+00:00January 15th, 2019|External News|0 Comments

ELIAS Animal Health Announces Positive Results in Treatment of Osteosarcoma in Dogs

ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS’ Autologous Prescription Product, known as ECI® (ELIAS Cancer Immunotherapy) resulted in a median survival time (MST) of 415 days in animals completing therapy – compared to historical treatment outcomes associated with surgery alone (134 days1). These results will be included in the ELIAS submission to USDA-CVB during the fourth quarter. ELIAS intends to initiate a larger field safety and efficacy study in early 2019. “We are very encouraged by our osteosarcoma clinical trial results as we move towards commercialization of ECI® for the veterinary community, while continuing to explore our platform technology in other cancers such as lymphoma,” said Noe Reyes, D.V.M., ELIAS medical director. The trial included 15 dogs diagnosed with osteosarcoma, [...]

By |2019-01-15T12:33:03+00:00October 25th, 2018|Elias News, Uncategorized|0 Comments

ELIAS presents preliminary canine osteosarcoma results at ACVIM

During the 2018 American College of Veterinary Internal Medicine Forum in June, ELIAS Animal Health, a clinical stage development company advancing novel treatments for companion animal cancer, shared preliminary canine osteosarcoma results for its cancer immunotherapy. According to study results presented by Brian Flesner, DVM, DACVIM (Oncology), University of Missouri, the company’s new ELIAS autologous cancer vaccine, featuring a patented vaccine and T cell infusion combination approach, demonstrated “impressive survival times and minimal side effects.” This cancer immunotherapeutic is being distributed as an experimental product under 9 CFR 103.3 to veterinarians treating dogs diagnosed with cancer. Efficacy and safety have not been established. One in four dogs will be impacted by cancer in their lifetimes, and cancer is the No. 1 cause of death in dogs older than 2. “There has been growing frustration in the veterinary profession with current treatment options, including chemotherapy and radiation, which have only modestly [...]

By |2019-01-15T12:33:03+00:00August 3rd, 2018|Elias News, Uncategorized|0 Comments

ELIAS Autologous Prescription Product Exceeds Expectations for Trial Safety and Efficacy

ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, shared promising preliminary canine osteosarcoma results for its cancer immunotherapy at the 2018 American College of Veterinary Internal Medicine (ACVIM) Forum in June. The study indicated its new ELIAS autologous cancer vaccine, featuring a patented combination of vaccine and T cell infusion approach, demonstrated impressive survival times and minimal side effects. This cancer immunotherapeutic is being distributed as an experimental product under 9 CFR 103.3 to veterinarians treating dogs diagnosed with cancer. Efficacy and safety have not been established. The results were presented by Brian Flesner, D.V.M., Dipl. ACVIM-Oncology, University of Missouri, and highlight continued progress within the immunotherapy arena for the treatment of canine cancer. One in four dogs will be impacted by cancer in their lifetimes and cancer is the No. 1 cause of death in dogs over the age of two. [...]

By |2019-01-15T12:33:04+00:00July 31st, 2018|Elias News, Uncategorized|0 Comments

Olathe biotech moves dog cancer treatment closer to market

A Kansas City-area animal health company is ramping up its efforts to take its cancer immunotherapy treatment to market. Elias Animal Health, a subsidiary of Olathe-based TVAX Biomedical Inc., applied for a conditional licensure of its treatment for dogs with bone cancer through the U.S. Department of Agriculture’s Center for Veterinary Biologics. Elias recently completed preliminary studies of its osteosarcoma treatment and will enroll for a pivotal study as the next step. On Thursday, the company will release the preliminary studies' results, which were promising enough for the company to start the licensing process. “Based on the positive data we’re seeing in the osteosarcoma study, we’ve started the licensing process, and we look forward to achieving the next milestone,” Elias CEO Tammie Wahaus said. “We’re very confident that it’s time to move forward.” Elias announced Wednesday that it plans to pursue a $4 million financing round to support commercialization, expansion [...]

By |2019-01-15T12:33:04+00:00June 14th, 2018|Elias News, Uncategorized|0 Comments

ELIAS gears up for $4m financing with addition of Stephanus and Sewell

ELIAS Animal Health has added considerable expertise to its board as it continues to work towards commercialization of its immunotherapy candidates and an upcoming financing round. The Olathe, Kansas-based firm has appointed Steve Sewell chief operating officer, as well as adding Lee Herron to its scientific advisory board, and Julia Stephanus and Kip Wiggins as board members. Mr. Sewell joins ELIAS after spending 10 years at Mars Petcare. He joined Mars as part of the Greenies brand acquisition and most recently served as market director of Mars Horsecare US. He has an extensive background in sales and marketing leadership in technology and consumer focused companies. Mr. Sewell also has expertise in strategic planning, new business development, distribution management, financial management and talent development. In his new role, Mr Sewell will be responsible for driving commercialization, sales and marketing at ELIAS, and will hold a key role in the firm's the [...]

By |2019-01-15T12:33:04+00:00June 14th, 2018|Elias News, Uncategorized|0 Comments

ELIAS Animal Health Cancer Immunotherapy Selected for State of the Art Presentation at VCS Mid‐Year Conference

ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has been selected by the Veterinary Cancer Society (VCS) for a “State of the Art” presentation at its Mid‐Year Conference in Anchorage, Alaska, March 10‐13. The mid‐year conference is focused on immunotherapy. Brenda Phillips, D.V.M., Dipl. ACVIM (Oncology) will present “T cell‐mediated immunotherapy for common canine cancers” during the state of the art presentation on Sunday, March 11. Dr. Phillips is a board‐certified specialist in medical oncology, practicing with Veterinary Specialty Hospital in San Diego, Calif. The clinical process, ongoing trials, management and experiences of this treatment being developed specifically for veterinary use in dogs will be discussed during the 30‐minute presentation. More data from the study is expected to be presented at the ACVIM Forum in June. ELIAS Animal Health has applied for conditional licensure of its autologous cancer immunotherapy for the treatment [...]

By |2019-01-15T12:33:04+00:00February 12th, 2018|Elias News, Uncategorized|0 Comments

ELIAS searches for more investment as trials near conclusion

US pet cancer therapy specialist ELIAS Animal Health has secured funding to take its current clinical trials through to completion. The firm's chief executive Tammie Wahaus said ELIAS closed $800,000 in funding from angel investors in April. However, the company is already on the lookout for its next injection of funds. "We're now looking for a commercialization funding round," she told Animal Pharm. "We'd like that to be in the first half of 2018." The Olathe, Kansas-headquartered company is expecting results from an osteosarcoma pivotal trial in the fall. In the longer-term, ELIAS has completed enrolment in a b-cell lymphoma trial with data set to be published a year from now. The firm owns the worldwide rights to TVAX Immunotherapy for use in companion animals, a treatment which it will market as ELIAS Cancer Immunotherapy. The technology has a two-stage process involving the vaccine and subsequent T cell treatment. ELIAS [...]

By |2019-01-15T12:33:04+00:00September 20th, 2017|Elias News, Uncategorized|0 Comments

ELIAS Animal Health Adds Clinical Trial Site for ECI™ for the Treatment of Canine Osteosarcoma

ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, is offering a fourth site for its clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™) as a treatment for newly- diagnosed appendicular osteosarcoma in dogs. The objective of this clinical trial is to determine whether ECI™ used in combination with surgery produces better outcomes than treatment with surgery alone. Efficacy will be determined by patient survival and comparing the outcomes to historical control data. The trial will be conducted at the Veterinary Specialty Hospital of San Diego. ELIAS Animal Health chief executive officer, Tammie Wahaus, shared a promising update on trial results to-date on Nov. 3, during the Collaborate2Cure series sponsored by Kansas City Area Life Sciences Institute and BioKansas. “Early clinical study results already show positive outcomes,” said Wahaus. “One patient, a 6-year old German Shorthaired Pointer, has [...]

By |2019-01-15T12:33:04+00:00November 15th, 2016|Elias News, Uncategorized|0 Comments

ELIAS Animal Health Announces First Patient Enrolled in Clinical Trial for ECI™ for the Treatment of Canine B-Cell Lymphoma

ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™), as a treatment for B-cell lymphoma in dogs. The majority of canine lymphomas are derived from B cells. While lymphoma is one of the most responsive cancers to chemotherapy, permanent cures in dogs are extremely rare and remissions are short-lived. There is a need for safer, more effective treatments for this disease. The objective of this clinical trial is to determine whether ECI™ used in combination with chemotherapy produces better outcomes than treatment with chemotherapy alone. Efficacy will be determined by patient survival and comparing the outcomes to historical control data. The trial will be conducted at the Kansas State University Veterinary Health Center. The ECI™ treatment protocol vaccinates a patient with its own unique [...]

By |2019-01-15T12:33:04+00:00August 24th, 2016|Elias News, Uncategorized|0 Comments